BA
MRNA icon

Bivin & Associates’s Moderna MRNA Stock Holding History

Bivin & Associates’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		$4K Hold
30
– – ﹤0.01% 197
2022
Q1 		$5K Sell
30
-86
-74% -$14.5K ﹤0.01% 209
2021
Q4 		$29K Buy
+116
New +$33.9K 0.03% 117

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bivin & Associates's MRNA Position: Q2 2022 in Review

Bivin & Associates held its Moderna (MRNA) position steady in Q2 2022 at 30 shares worth $4K. The position accounts for ﹤0.01% of the portfolio, ranked #197.

Bivin & Associates first reported a position in MRNA in Q4 2021 and has held it in 3 quarters since. The position peaked at $29K in Q4 2021. 982 funds tracked by Wall St. Rank hold MRNA as of Q2 2022.

  • Bivin & Associates held 30 shares of Moderna worth $4K as of Q2 2022.
  • Bivin & Associates left its Moderna share count unchanged in Q2 2022.
  • Moderna made up ﹤0.01% of Bivin & Associates's portfolio in Q2 2022, its #197 holding.
  • Bivin & Associates first reported a position in Moderna in Q4 2021 and has held it in 3 quarters since.
  • Bivin & Associates's Moderna position peaked at $29K in Q4 2021.
  • 982 funds tracked by Wall St. Rank held Moderna as of Q2 2022.

Based on Bivin & Associates's 13F filing for Q2 2022, filed 11 Aug 2022.